Fig. 2From: Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysisIncidence and prevalence of AEs over the 12-month follow-up period among PNA-treated patients with HCL. AEs were identified at any position (primary, secondary) on the claim. AE adverse event, HCL hairy cell leukemia, PNA purine nucleoside analogBack to article page